

## Dietary Approaches to Prevent and Treat Hypertension A Scientific Statement From the American Heart Association

Lawrence J. Appel, MD, MPH; Michael W. Brands, PhD; Stephen R. Daniels, MD, PhD;  
Njeri Karanja, PhD; Patricia J. Elmer, PhD; Frank M. Sacks, MD

**Abstract**—A substantial body of evidence strongly supports the concept that multiple dietary factors affect blood pressure (BP). Well-established dietary modifications that lower BP are reduced salt intake, weight loss, and moderation of alcohol consumption (among those who drink). Over the past decade, increased potassium intake and consumption of dietary patterns based on the “DASH diet” have emerged as effective strategies that also lower BP. Of substantial public health relevance are findings related to blacks and older individuals. Specifically, blacks are especially sensitive to the BP-lowering effects of reduced salt intake, increased potassium intake, and the DASH diet. Furthermore, it is well documented that older individuals, a group at high risk for BP-related cardiovascular and renal diseases, can make and sustain dietary changes. The risk of cardiovascular disease increases progressively throughout the range of BP, beginning at 115/75 mm Hg. In view of the continuing epidemic of BP-related diseases and the increasing prevalence of hypertension, efforts to reduce BP in both nonhypertensive and hypertensive individuals are warranted. In nonhypertensive individuals, dietary changes can lower BP and prevent hypertension. In uncomplicated stage I hypertension (systolic BP of 140 to 159 mm Hg or diastolic BP of 90 to 99 mm Hg), dietary changes serve as initial treatment before drug therapy. In those hypertensive patients already on drug therapy, lifestyle modifications, particularly a reduced salt intake, can further lower BP. The current challenge to healthcare providers, researchers, government officials, and the general public is developing and implementing effective clinical and public health strategies that lead to sustained dietary changes among individuals and more broadly among whole populations. (*Hypertension*. 2006;47:296-308.)

**Key Words:** AHA Scientific Statements ■ blood pressure ■ diet ■ hypertension

Elevated blood pressure (BP) remains an extraordinarily common and important risk factor for cardiovascular and renal diseases, including stroke, coronary heart disease, heart failure, and kidney failure. According to the most recent NHANES survey (1999 to 2000), 27% of adult Americans have hypertension (systolic BP  $\geq$ 140 mm Hg, diastolic BP  $\geq$ 90 mm Hg, or use of antihypertensive medication), and another 31% have prehypertension (systolic BP of 120 to 139 mm Hg or diastolic BP of 80 to 89 mm Hg, not on medication).<sup>1</sup> Prehypertensive individuals have a high probability of developing hypertension and carry an excess risk of cardiovascular disease as compared with those with a normal BP (systolic BP  $<$ 120 mm Hg and diastolic BP  $<$ 80 mm Hg).<sup>2</sup> It has been estimated that among adults  $>$ 50 years of age, the lifetime risk of developing hypertension approaches 90%.<sup>3</sup> Recent data indicate that the prevalence of

hypertension is increasing<sup>4</sup> and that control rates among those with hypertension remain low.<sup>5</sup> On average, blacks have higher BP than nonblacks,<sup>4</sup> as well as an increased risk of BP-related complications, particularly stroke<sup>6,7</sup> and kidney failure.<sup>8</sup>

BP is a strong, consistent, continuous, independent, and etiologically relevant risk factor for cardiovascular and renal disease.<sup>9</sup> Notably, no evidence of a BP threshold exists; ie, the risk of cardiovascular disease increases progressively throughout the range of BP, including the prehypertensive range.<sup>10</sup> It has been estimated that almost a third of BP-related deaths from coronary heart disease occur in individuals with BP in the nonhypertensive range.<sup>11</sup>

Elevated BP results from environmental factors, genetic factors, and interactions among these factors. Of the environmental factors that affect BP (diet, physical inactivity, toxins,

The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.


This statement was approved by the American Heart Association Science Advisory and Coordinating Committee on November 4, 2005. A single reprint is available by calling 800-242-8721 (US only) or writing the American Heart Association, Public Information, 7272 Greenville Ave, Dallas, TX 75231-4596. Ask for reprint No. 71-0353. To purchase additional reprints: up to 999 copies, call 800-611-6083 (US only) or fax 413-665-2671; 1000 or more copies, call 410-528-4121, fax 410-528-4264, or e-mail kramsay@lww.com. To make photocopies for personal or educational use, call the Copyright Clearance Center, 978-750-8400.

Expert peer review of AHA Scientific Statements is conducted at the AHA National Center. For more on AHA statements and guidelines development, visit <http://www.americanheart.org/presenter.jhtml?identifier=3023366>.

© 2006 American Heart Association, Inc.

*Hypertension* is available at <http://www.hypertensionaha.org>

DOI: 10.1161/01.HYP.0000202568.01167.B6



**Figure 1.** Estimated effects of population-wide shifts in systolic BP distributions on mortality. Adapted with permission from Stamler.<sup>12</sup>

and psychosocial factors), dietary factors have a prominent, and likely predominant, role in BP homeostasis. In nonhypertensive individuals, including those with prehypertension, dietary changes that lower BP have the potential to prevent hypertension and more broadly to reduce BP and thereby lower the risk of BP-related clinical complications. Indeed, even an apparently small reduction in BP, if applied to an entire population, could have an enormous beneficial impact. For instance, it has been estimated that a 3–mm Hg reduction in systolic BP could lead to an 8% reduction in stroke mortality and a 5% reduction in mortality from coronary heart disease (see Figure 1).<sup>12</sup> In uncomplicated stage I hypertension (systolic BP of 140 to 159 mm Hg or diastolic BP of 90 to 99 mm Hg), dietary changes can serve as initial treatment before the start of drug therapy. Among hypertensive individuals who are already on drug therapy, dietary changes, particularly a reduced salt intake, can further lower BP and facilitate medication step-down. In general, the extent of BP reduction from dietary therapies is greater in hypertensive than in nonhypertensive individuals.

The purpose of this scientific statement, which updates prior AHA recommendations,<sup>13</sup> is to summarize evidence on the efficacy of diet-related factors that lower BP and to present recommendations for healthcare providers, policy makers, and the general public. This document relies primarily on evidence as compiled in systematic reviews. Individual studies that document seminal findings are also discussed. Recommendations in this document are broadly consistent with those expressed in federal policy documents.<sup>9,14</sup>

### Dietary Factors That Lower BP

See Table 1 for a summary of diet-related lifestyle modifications that effectively lower BP.

#### Weight Loss

A substantial and largely consistent body of evidence from observational studies and clinical trials documents that weight is directly associated with BP. The importance of this relationship is reinforced by the high and increasing prevalence of overweight and obesity in the United States and throughout the world. Approximately 65% of US adults have a body mass index (BMI)  $\geq 25$  kg/m<sup>2</sup> and therefore are classified as either overweight or obese; >30% of US adults are clinically obese (BMI  $\geq 30$  kg/m<sup>2</sup>).<sup>15</sup> In US children and adolescents, the prevalence of overweight has increased over the past decade, as have levels of BP.<sup>16</sup>


With rare exception, clinical trials have documented that weight loss lowers BP. Importantly, reductions in BP occur before, and without, attainment of a desirable body weight. In one meta-analysis that aggregated results across 25 trials, mean systolic and diastolic BP reductions from an average weight loss of 5.1 kg were 4.4 and 3.6 mm Hg, respectively.<sup>17</sup> In subgroup analyses, BP reductions were similar for nonhypertensive and hypertensive subjects but were greater in those who lost more weight. Within-trial dose–response analyses<sup>18,19</sup> and prospective observational studies<sup>20</sup> also document that greater weight loss leads to greater BP reduction.

Additional trials have documented that modest weight loss, with or without sodium reduction, can prevent hypertension by  $\approx 20\%$  among overweight, prehypertensive individuals<sup>21</sup> and can facilitate medication step-down and drug withdrawal.<sup>22,23</sup> Lifestyle intervention trials have uniformly achieved short-term weight loss, primarily through a reduction in total caloric intake. In several instances, substantial weight loss has been sustained over  $\geq 3$  years.<sup>23,24</sup> Maintaining a high level of physical activity is well recognized as a critical factor in sustaining weight loss. Whether weight loss can blunt the age-related rise in BP is unclear. In one trial with long-term follow-up, those individuals who sustained a >10-lb weight loss achieved a lower BP that nonetheless rose over time.<sup>19</sup>

In aggregate, available evidence strongly supports weight reduction, ideally attainment of a BMI <25 kg/m<sup>2</sup>, as an effective approach to prevent and treat hypertension. More importantly, in view of the well-recognized difficulties of sustaining weight loss, efforts to prevent weight gain among those who have normal body weight are critically important.

**TABLE 1. Diet-Related Lifestyle Modifications That Effectively Lower BP**

Lifestyle Modification	Recommendation
Weight loss	For overweight or obese persons, lose weight, ideally attaining a BMI <25 kg/m <sup>2</sup> ; for nonoverweight persons, maintain desirable BMI <25 kg/m <sup>2</sup>
Reduced salt intake	Lower salt (sodium chloride) intake as much as possible, ideally to $\approx 65$ mmol/d sodium (corresponding to 1.5 g/d of sodium or 3.8 g/d sodium chloride)
DASH-type dietary patterns	Consume a diet rich in fruits and vegetables (8–10 servings/d), rich in low-fat dairy products (2–3 servings/d), and reduced in saturated fat and cholesterol
Increased potassium intake	Increase potassium intake to 120 mmol/d (4.7 g/d), which is also the level provided in DASH-type diets
Moderation of alcohol intake	For those who drink alcohol, consume $\leq 2$ alcoholic drinks/d (men) and $\leq 1$ alcoholic drink/d (women)



**Figure 2.** Mean systolic BP changes in the DASH-Sodium trial. Solid lines indicate the effects of sodium reduction in the 2 diets; hatched lines, the effects of the DASH diet at each sodium level. Adapted with permission from Sacks et al.<sup>28</sup>

### Reduced Salt Intake

On average, as dietary salt (sodium chloride) intake rises, so does BP. Evidence includes results from animal studies, epidemiological studies, clinical trials, and meta-analyses of trials. To date, >50 randomized trials have been conducted. In one of the most recent meta-analyses,<sup>25</sup> a median reduction in urinary sodium of  $\approx 1.8$  g/d (78 mmol/d) lowered systolic BP and diastolic BP by 2.0 and 1.0 mm Hg in nonhypertensive and by 5.0 and 2.7 mm Hg in hypertensive individuals.

The most persuasive evidence about the effects of salt on BP comes from rigorously controlled, dose-response trials.<sup>26–28</sup> Each of these 3 trials tested at least 3 sodium levels, and each documented statistically significant, direct, progressive dose-response relationships. The largest of the dose-response trials, the DASH-Sodium trial, tested the effects of 3 different sodium intakes separately in 2 distinct diets: the DASH (Dietary Approaches to Stop Hypertension) diet (see subsequent section for a complete description) and a control diet more typical of what Americans eat. As estimated from 24-hour urine collections, the 3 sodium levels (lower, intermediate, and higher) provided 65, 107, and 142 mmol/d, respectively, corresponding to approximate intakes of 1.5, 2.5, and 3.3 g, respectively.

The main results of the DASH-Sodium trial are shown in Figure 2. The BP response to sodium reduction, while direct and progressive, was nonlinear. Specifically, decreasing sodium intake by  $\approx 0.9$  g/d (40 mmol/d) caused a greater lowering of BP when the starting sodium intake was 100 mmol/d than when it was above this level. In subgroup analyses of the DASH-Sodium trial,<sup>29,30</sup> reduced sodium intake significantly lowered BP in each of the major subgroups studied (ie, men, women, blacks, and nonblacks). Importantly, sodium reduction significantly lowered BP in nonhypertensive individuals on both diets.

In addition to reduced BP, clinical trials have documented that a reduced sodium intake can prevent hypertension (relative risk reduction of  $\approx 20\%$  with or without concomitant weight loss),<sup>21</sup> can lower BP in the setting of antihypertensive medication,<sup>31,32</sup> and can facilitate hypertension control.<sup>22,23</sup> In observational studies, reduced sodium intake is associated with a blunted age-related rise in systolic BP.<sup>33</sup> In other observational studies, reduced salt intake is associated with a

reduced risk of atherosclerotic cardiovascular events<sup>34,35</sup> and congestive heart failure.<sup>36</sup>

The BP response to changes in dietary sodium intake is heterogeneous<sup>37</sup> (as is the BP response to other dietary changes). Despite use of the terms “salt sensitive” and “salt resistant” to classify individuals in research studies, the change in BP in response to a change in salt intake is not binary.<sup>38</sup> Rather, the reduction in BP from a reduced sodium intake has a continuous distribution, with individuals having greater or lesser degrees of BP reduction. In general, the effects of sodium reduction on BP tend to be greater in blacks; middle-aged and older persons; and individuals with hypertension, diabetes, or chronic kidney disease. These groups tend to have a less responsive renin-angiotensin-aldosterone system.<sup>39</sup> It has been hypothesized that salt sensitivity is a phenotype that reflects subclinical renal disease.<sup>40</sup> As discussed later in this statement, genetic and dietary factors also influence the response to sodium reduction. For example, the rise in BP for a given increase in sodium intake is blunted in the setting of either the DASH diet<sup>28</sup> or high potassium intake.<sup>41,42</sup>

Some salt intake is required. Recently, an Institute of Medicine committee set 1.5 g/d (65 mmol/d) sodium as an adequate intake level, primarily to ensure nutrient adequacy.<sup>43</sup> Although a sodium intake below this level is associated with lower BP,<sup>44</sup> little information is available about the nutrient content of diets that provide <1.5 g/d of sodium. From the DASH-Sodium trial, it is apparent that Western-type diets can provide this level of sodium intake and that such a diet can also provide adequate levels of other nutrients.<sup>45</sup> Because the relationship between sodium intake and BP is direct and progressive without an apparent threshold, it is difficult to set an upper level of sodium intake, which also could be 1.5 g/d (65 mmol/d). However, in view of the available food supply and the currently high levels of sodium consumption, a reduction in sodium intake to 1.5 g/d (65 mmol/d) is not easily achievable at present. In the interim, a reasonable recommendation is an upper limit of 2.3 g/d (100 mmol/d), which is similar to earlier recommendations for the prevention and treatment of hypertension.<sup>9,14</sup>

In aggregate, available data strongly support current, population-wide recommendations to lower salt intake. To reduce salt intake, consumers should choose foods low in salt and limit the amount of salt added to food. However, because >75% of consumed salt comes from processed foods,<sup>46</sup> any meaningful strategy to reduce salt intake must involve the efforts of food manufacturers and restaurants, which should progressively reduce the salt added to foods by 50% over the next 10 years.<sup>9,47</sup>

### Increased Potassium Intake

High potassium intake is associated with reduced BP. Evidence includes animal studies, observational epidemiological studies, >30 clinical trials, and meta-analyses of these trials. Although data from individual trials have been inconsistent, 3 meta-analyses of these trials have documented a significant inverse relationship between potassium intake and BP in nonhypertensive and hypertensive individuals.<sup>48–50</sup> In the meta-analysis by Whelton et al,<sup>49</sup> average systolic and dia-



stolic BP reductions associated with a net increase in urinary potassium excretion of 2 g/d (50 mmol/d) were 4.4 and 2.5 mm Hg in hypertensive and 1.8 and 1.0 mm Hg in nonhypertensive individuals.

Because no trial has tested the effects of  $\geq 3$  levels of dietary potassium intake on BP, inferences on the dose–response relationship between potassium and BP must be drawn from individual trials. Available data suggest that increased potassium has beneficial effects on BP in the setting of a low intake (eg, 1.3 to 1.4 g/d, or 35 to 40 mmol/d)<sup>51</sup> or a much higher intake (eg, 3.3 g/d, or 84 mmol/d).<sup>52</sup> Potassium reduces BP to a greater extent in blacks than in whites.<sup>49</sup> In several trials, the effects of increased potassium intake in blacks have been particularly striking.<sup>53</sup>

Because a high potassium intake can be achieved through diet rather than pills and because potassium derived from foods is also accompanied by a variety of other nutrients, the preferred strategy to increase potassium intake is to consume foods such as fruits and vegetables that are rich in potassium, rather than supplements. In the DASH trial, the 2 groups that increased fruit and vegetable consumption both lowered BP.<sup>28,54</sup> The 2100-kcal version of the DASH diet provides  $\approx 4.7$  g/d (120 mmol/d) potassium.<sup>55</sup> Another trial documented that increased fruit and vegetable consumption lowers BP, but it did not specify the amount of potassium provided in the fruits and vegetables.<sup>56</sup>

The effects of potassium on BP depend on the concurrent intake of salt and vice versa. Specifically, an increased intake of potassium has a greater BP-lowering effect in the context of a higher salt intake and lesser BP reduction in the setting of a lower salt intake. Conversely, the BP reduction from a reduced salt intake is greatest when potassium intake is low. For example, a high potassium intake (120 mmol/d) blunted the rise in BP in response to increased salt intake in 24 nonhypertensive black men and to a lesser extent in 14 nonblacks.<sup>42</sup> In a 2 $\times$ 2 factorial trial that tested the effects of reduced salt intake and increased potassium intake, alone or together, on BP in 212 hypertensives,<sup>57</sup> a reduced sodium intake lowered BP to the same extent as an increased potassium intake; however, the combination of both sodium reduction and increased potassium did not further lower BP. These data are consistent with subadditive effects of reduced salt intake and increased potassium intake on BP.

The dearth of dose–response trials precludes a firm recommendation for a specific level of potassium intake as a means to lower BP. However, it is reasonable to set the recommended potassium intake level as 4.7 g/d (120 mmol/d). This level of intake corresponds to the average total potassium intake in clinical trials,<sup>49</sup> the highest dose in the one available dose–response trial,<sup>42</sup> and the potassium content of the DASH diet intake.<sup>54</sup> It is also the adequate intake level set by an Institute of Medicine committee.<sup>43</sup> On the basis of data from NHANES III, the average intake of potassium is 2.9 to 3.2 mg/d (74 to 82 mmol/d) in adult men and 2.1 to 2.3 g/d (54 to 59 mmol/d) in adult women; only 10% of men and <1% of women are consuming  $\geq 4.7$  g/d (120 mmol/d) potassium.<sup>43</sup>

In the generally healthy population with normal kidney function, a potassium intake from foods  $>4.7$  g/d (120 mmol/d) poses no risk because excess potassium is readily excreted in the urine. However, in individuals whose urinary potassium excretion is impaired, a potassium intake  $<4.7$  g/d (120 mmol/d) is appropriate because of adverse cardiac effects (arrhythmias) from hyperkalemia. Common drugs that can substantially impair potassium excretion are ACE inhibitors, angiotensin receptor blockers, nonsteroidal antiinflammatory agents, and potassium-sparing diuretics. Medical conditions associated with impaired potassium excretion include diabetes, chronic renal insufficiency, end-stage renal disease, severe heart failure, and adrenal insufficiency. Elderly individuals are at increased risk of hyperkalemia because they often have one or more of these conditions or take one or more medications that impair potassium excretion.

The available evidence is insufficient to identify the level of kidney function at which individuals with chronic kidney disease are at increased risk for hyperkalemia from high potassium intake. However, an expert panel recommended that individuals with stage 3 or 4 chronic kidney disease, ie, an estimated glomerular filtration rate  $<60$  mL  $\cdot$  min<sup>-1</sup>  $\cdot$  1.73 m<sup>-2</sup>, restrict their intake of potassium.<sup>58</sup>

### Moderation of Alcohol Intake

Observational studies and clinical trials have documented a direct, dose-dependent relationship between alcohol intake and BP, particularly as the intake of alcohol increases above  $\approx 2$  drinks per day.<sup>59,60</sup> Importantly, this relationship has been shown to be independent of potential confounders such as age, obesity, and salt intake.<sup>61</sup> Although some studies have shown that the alcohol–hypertension relationship also extends into the light drinking range ( $\leq 2$  drinks per day), this is the range in which alcohol may reduce coronary heart disease risk.

A recent meta-analysis of 15 randomized controlled trials<sup>60</sup> reported that decreased consumption of alcohol (median reduction in self-reported alcohol consumption, 76%; range, 16% to 100%) reduced systolic and diastolic BPs by 3.3 and 2.0 mm Hg, respectively. BP reductions were similar in nonhypertensive and hypertensive individuals. Importantly, the relationship between reduction in mean percentage of alcohol and decline in BP was dose dependent.

In aggregate, available evidence supports moderation of alcohol intake (among those who drink) as an effective approach to lower BP. Alcohol consumption should be limited to  $\leq 2$  alcoholic drinks per day in most men and  $\leq 1$  alcoholic drink per day in women and lighter-weight persons. Note that 1 drink is defined as 12 oz of regular beer, 5 oz of wine (12% alcohol), and 1.5 oz of 80-proof distilled spirits.

### Whole Dietary Patterns

#### Vegetarian Diets

Vegetarian diets have been associated with low BP. In industrialized countries, where elevated BP is commonplace, individuals who consume a vegetarian diet have markedly lower BPs than do nonvegetarians.<sup>62,63</sup> In these observational studies, vegetarians also experience a lower age-related rise

in BP. Some of the lowest BPs observed in industrialized countries have been documented in strict vegetarians (macrobiotics) living in Massachusetts.<sup>64</sup>


Several aspects of a vegetarian lifestyle might lower BP, including nondietary factors (eg, physical activity), established dietary risk factors (eg, reduced weight, increased potassium, and low-to-moderate alcohol intake), and other aspects of vegetarian diets (eg, high fiber, no meat). To a variable extent, observational studies have controlled for the well-established determinants of BP. For instance, in a study of Seventh Day Adventists, analyses were adjusted for weight but not dietary sodium or potassium.<sup>63</sup> Trial evidence, albeit limited, indicates that nondietary factors and established dietary risk factors are not fully responsible for the BP-lowering effects of vegetarian diets and that some other aspects of vegetarian diets lower BP. In the 2 available trials, one in nonhypertensive individuals<sup>65</sup> and another in hypertensive persons,<sup>66</sup> lactoovovegetarian diets reduced systolic BP by  $\approx 5$  mm Hg but had equivocal effects on diastolic BP.

### The DASH Diet and Related Dietary Patterns

A series of 3 large, controlled feeding studies tested the effects of dietary patterns on BP.<sup>28,54,67</sup> The first trial was a randomized feeding study that compared 3 dietary patterns.<sup>54</sup> Of the 3 diets studied, the most effective diet, now called the DASH diet, emphasized fruits, vegetables, and low-fat dairy products; included whole grains, poultry, fish and nuts; and was reduced in fats, red meat, sweets, and sugar-containing beverages. Accordingly, it was rich in potassium, magnesium, calcium, and fiber and was reduced in total fat, saturated fat, and cholesterol; it also was slightly increased in protein.<sup>55</sup> It is likely that several aspects of the diet, rather than just one nutrient or food, reduced BP. Among all participants, the DASH diet significantly lowered mean systolic BP by 5.5 mm Hg and mean diastolic BP by 3.0 mm Hg, each net of changes in the control diet. A second diet, which emphasized just fruits and vegetables, also significantly reduced BP but to a lesser extent, about half of the effect of the DASH diet. The effects of the diets were rapid, occurring within only 2 weeks (see Figure 3).

The DASH diet significantly lowered BP in all major subgroups (men, women, blacks, nonblacks, hypertensive individuals, and nonhypertensive individuals).<sup>68</sup> However, the effects of the DASH diet in the black participants (systolic and diastolic BP reductions of 6.9 and 3.7 mm Hg) were significantly greater than corresponding effects in white participants (3.3 and 2.4 mm Hg). The effects in hypertensive individuals (systolic and diastolic BP reductions of 11.6 and 5.3 mm Hg) were striking and were significantly greater than the corresponding effects in nonhypertensive individuals (3.5 and 2.2 mm Hg). In a subsequent trial that enrolled a similar population,<sup>28</sup> the DASH diet significantly lowered BP at each of 3 sodium levels (Figure 2); however, the extent of BP reduction was less when the sodium level was low (1.5 g/d).

The OmniHeart trial compared the effects of 3 healthy dietary patterns: a diet rich in carbohydrate (58% of total calories), a second diet rich in protein (about half from plant sources), and a third diet rich in unsaturated fat (predominantly monounsaturated fat).<sup>67</sup> Similar to the DASH diet,



**Figure 3.** BP by week during the DASH feeding study in 3 diets: control diet, fruits and vegetables diet, and the DASH diet. Adapted with permission from Appel et al.<sup>54</sup>

each of the OmniHeart diets was reduced in saturated fat and cholesterol and rich in fruit, vegetables, fiber, potassium, and other minerals at recommended levels. As displayed in Figure 4, each diet lowered systolic BP. Furthermore, substituting some of the carbohydrate ( $\approx 10\%$  of total kcal) with either protein (about half from plant sources) or unsaturated fat (mostly monounsaturated fat) further lowered BP.

The DASH diet and the diets studied in the OmniHeart trial are safe and broadly applicable to the general population. However, because of their relatively high potassium and phosphorus content (in all diets) and high protein content (in the DASH diet and the protein-rich diet in OmniHeart), these diets are not recommended in persons with stage 3 or 4 chronic kidney disease, ie, an estimated glomerular filtration rate  $< 60 \text{ mL} \cdot \text{min}^{-1} \cdot 1.73 \text{ m}^{-2}$ .<sup>58</sup>


## Dietary Factors With Limited or Uncertain Effect on BP

### Fish Oil Supplementation

Several predominantly small clinical trials and meta-analyses of these trials<sup>69–71</sup> have documented that high-dose omega-3 polyunsaturated fatty acid (commonly called fish oil) supplements can lower BP in hypertensive individuals. In nonhypertensive individuals, BP reductions tend to be small or nonsignificant. The effect of fish oil appears to be dose dependent, with BP reductions occurring at relatively high doses—namely,  $\geq 3$  g/d. In hypertensive individuals, average systolic and diastolic BP reductions were 4.0 and 2.5 mm Hg, respectively.<sup>71</sup> Side effects, including belching and a fishy taste, are commonplace. In view of the high dose required to lower BP and the side-effect profile, fish oil supplements cannot be routinely recommended as a means to lower BP.

### Fiber

Dietary fiber consists of the indigestible components of food from plants. Evidence from observational studies and several



**Figure 4.** Effects of 3 healthy dietary patterns tested in the OmniHeart feeding study on systolic BP (CARB [similar to the DASH diet], PROT [rich in protein, about half from plant sources], and UNSAT [rich in monounsaturated fat]) in all participants (A) and in hypertensive participants (B). Data derived from Appel et al.<sup>67</sup>

clinical trials suggests that increased fiber intake may reduce BP.<sup>72</sup> More than 40 randomized trials of dietary fiber supplementation have been conducted. Still, most did not have BP as their primary outcome, and many had a multicomponent intervention. A meta-analysis of these trials,<sup>73</sup> restricted to the 20 trials that increased just fiber intake, documented that supplemental fiber (average increase, 14 g/d) was associated with net systolic and diastolic BP reductions of 1.6 and 2.0 mm Hg, respectively. Subsequently, in a large randomized trial,<sup>74</sup> supplemental fiber did not lower BP. Overall, data are insufficient to recommend an increased intake of fiber alone as a means to lower BP.

### Calcium and Magnesium

Evidence that calcium intake might affect BP comes from a variety of sources, including animal studies, observational studies, clinical trials, and meta-analyses. In a meta-analysis of 23 observational studies, Cappuccio et al<sup>75</sup> reported an inverse association between BP and dietary calcium intake (as measured by 24-hour dietary recalls or food frequency questionnaires). However, the size of the effect was relatively small, and there was evidence of publication bias and of heterogeneity across studies. Subsequently, meta-analyses of clinical trials documented modest reductions in systolic and

diastolic BPs of 0.9 to 1.4 mm Hg and 0.2 to 0.8 mm Hg, respectively, with calcium supplementation (400 to 2000 mg/d).<sup>76–78</sup> Also, some evidence indicates that the level of calcium intake may affect the BP response to salt. In 3 small trials, calcium supplementation attenuated the effect of a high sodium intake on BP.<sup>79–81</sup>

The body of evidence implicating magnesium as a major determinant of BP is inconsistent. In observational studies, often cross-sectional in design, a common finding is an inverse association of dietary magnesium with BP. In a pooled analysis of 29 observational studies, there was a negative association between dietary magnesium and BP.<sup>82</sup> However, in a meta-analysis of 20 randomized clinical trials, no clear effect of magnesium intake on BP was evident.<sup>83</sup>

Overall, data are insufficient to recommend either supplemental calcium or magnesium as a means to lower BP.

### Carbohydrate

An evolving but complex body of evidence suggests that both amount and type of carbohydrate intake affect BP.<sup>84</sup> Worldwide, there are many populations that eat carbohydrate-rich, low-fat diets that have low BP levels as compared with Western countries.<sup>62</sup> Still, the results of observational studies that specifically examined the effect of carbohydrate intake on BP have been inconsistent (direct in one study,<sup>85</sup> no association in another,<sup>86</sup> and inverse association in another<sup>87</sup>). In early, albeit small, trials, increasing carbohydrate by reducing total fat generally did not reduce BP.<sup>88</sup>

In contrast, the recently completed OmniHeart feeding study documented that in the setting of a healthy diet similar to the DASH diet, partial substitution of carbohydrate with either protein (about half from plant sources) or monounsaturated fat lowers BP; importantly, the total dietary glycemic index, an indicator of the type of carbohydrate, was moderate and similar in each diet.<sup>67</sup> Note that the incremental effects on BP of replacing some carbohydrate with protein or monounsaturated fat were modest as compared with the large effects of the carbohydrate-rich diet studied in the OmniHeart study (see Figure 4)<sup>67</sup> or the DASH diet itself (Figure 3).<sup>54</sup>

A few trials have also tested the effects of short-term sugar consumption on BP. In several<sup>89,90</sup> but not all studies,<sup>91</sup> consumption of sugars raised BP. Consistent with these studies are results from a weight loss trial in which a low-glycemic-index diet reduced BP to a greater extent than a standard high-glycemic-index diet.<sup>92</sup> Overall, additional research is warranted before specific recommendations can be made about the amount and type of carbohydrate.

### Intake of Fats Other Than n-3 PUFA

Total fat includes saturated fat, omega-3 polyunsaturated fat, omega-6 polyunsaturated fat, and monounsaturated fat. Although early studies focused on the effects of total fat intake on BP, there is a plausible biological basis to hypothesize that certain types of fat (eg, omega-3 polyunsaturated fat) might reduce BP and that other types of fat (eg, saturated fat) might raise BP. Hence, the direction of the BP effect might be direct (positive) or inverse, depending on the type of fats consumed.



**Saturated Fat**

Several observational studies and a few clinical trials have assessed the impact of saturated fat on BP. In the vast majority of studies, including 2 prospective observational studies, the Nurses Health Study and the Health Professional Follow-up Study, saturated fat intake (percent kilocalories as determined by a food frequency questionnaire) was not associated with incident hypertension.<sup>93,94</sup> In the few available trials, diet interventions that focused only on reducing saturated fat had no significant effect on BP.<sup>88</sup> Because most trials tested diets that were both reduced in saturated fat and increased in polyunsaturated fat, the absence of an effect on BP also suggests no benefit from polyunsaturated fat.

**Omega-6 Polyunsaturated Fat Intake**

Dietary intake of omega-6 polyunsaturated fat (mainly linoleic acid in Western diets) has little effect on BP. In an overview of cross-sectional studies that correlated BP with tissue or blood levels of omega-6 polyunsaturated fat, there was no apparent relationship (no association in 8 studies, inverse association in 4 studies, and 1 positive association).<sup>88</sup> Prospective observational studies and clinical trials have likewise been unresponsive of a relationship.<sup>88,93,94</sup>

**Monounsaturated Fat Intake**

Few studies have assessed the relationship between monounsaturated fat intake and BP. Five of 7 cross-sectional studies did not detect a relationship,<sup>88</sup> and neither of 2 prospective studies conducted in the United States documented an effect of monounsaturated fat intake on subsequent hypertension.<sup>93,94</sup> Likewise, evidence from the earliest clinical trials did not support a relationship between monounsaturated fat and BP.<sup>88</sup> However, subsequent trials have shown that diets rich in monounsaturated fats lower BP.<sup>95,96</sup> In the recently completed OmniHeart study, partial substitution of carbohydrate with monounsaturated fat lowered BP. Overall, although increased monounsaturated fat appears to lower BP, this relationship often is confounded by a concomitant reduction in carbohydrate intake. Hence, the effect of monounsaturated fat intake per se on BP is uncertain.<sup>67</sup>

**Protein Intake**

An extensive, and generally consistent, body of evidence from observational studies has documented significant inverse associations between protein intake and BP.<sup>73,97</sup> Recently, 2 major observational studies, the International Study on Macronutrients and Blood Pressure (INTERMAP) and the Chicago Western Electric Study, have documented significant inverse relationships between protein intake and BP.<sup>87,98</sup> In these studies, protein from plant sources was associated with lower BP, whereas protein from animal sources had no effect.

Some trials have also examined the effects of increased protein intake on BP. Most of these trials tested soy-based interventions on BP. In some but not all of these trials, soy supplementation replacing carbohydrate reduced BP.<sup>99,100</sup> In a recent large trial conducted in China, replacing carbohydrate with increased protein intake from soy supplements lowered BP.<sup>101</sup> In the recently completed OmniHeart study, partial substitution of carbohydrate with protein (about half

from plant sources) lowered BP.<sup>67</sup> In aggregate, data from clinical trials, in conjunction with evidence from observational studies, support the hypothesis that substitution of carbohydrate with increased intake of protein, particularly from plants, can lower BP. However, it remains uncertain whether the effects result from increased protein or reduced carbohydrate.

**Cholesterol**

Few studies have examined the effect of dietary cholesterol intake on BP. In the Multiple Risk Factor Intervention Trial (MRFIT) cohort, there were significant, direct relationships between cholesterol intake (in milligrams per day) and both systolic and diastolic BPs.<sup>85</sup> The Keys score was also associated with diastolic but not systolic BP. In longitudinal multivariate analyses from the Western Electric Study, there were significant positive relationships of change in systolic BP over 8 years with both dietary cholesterol and Keys score.<sup>87</sup> Still, despite these consistent reports from 2 studies, the paucity of evidence precludes any conclusion about a relationship between dietary cholesterol intake and BP.

**Vitamin C**

Laboratory studies, depletion–repletion studies, and epidemiological studies suggest that increased vitamin C intake or status is associated with lower BP. In a systematic review by Ness et al,<sup>102</sup> 10 of 14 cross-sectional studies reported an inverse association between plasma vitamin C and BP, and 3 of 4 reported an inverse association with vitamin C intake. The 2 nonrandomized and 4 randomized controlled trials were all small, and results were inconsistent; effect sizes ranged from 0 to >10 mm Hg in systolic BP reduction. In a subsequent trial, 500 mg of vitamin C had no effect on BP over the course of 5 years.<sup>103</sup> In summary, it remains unclear whether an increased intake of vitamin C reduces BP.

**Gene–Diet Interactions**

A rapidly increasing body of evidence indicates that genetic factors affect BP levels and the BP response to dietary changes. Most of the available evidence has focused on genetic factors that influence the BP response to salt intake. Several genotypes that influence BP have been identified. Most of these genotypes influence the renin-angiotensin-aldosterone axis or renal salt handling. In a line of investigation that focused on mendelian diseases associated with either high or low BP, 6 genes associated with higher BP and another 8 genes associated with lower BP have been identified.<sup>104</sup> It is noteworthy that each of these genes regulates renal sodium chloride handling; mutations that increase net sodium chloride reabsorption raise BP, whereas mutations that reduce sodium chloride reabsorption lower BP.

Several trials have examined the effects of specific genotypes on the BP response to dietary changes. In 3 trials, genetic variation of the angiotensinogen gene modified the BP response to changes in salt intake in nonblacks<sup>26,105,106</sup> and the BP responses to weight loss<sup>105</sup> and the DASH diet.<sup>107</sup> Polymorphism of the  $\alpha$ -adducin gene also appears to affect the BP response to salt.<sup>108</sup> Finally, the ACE insertion-deletion polymorphism may affect the BP response to weight loss.<sup>109</sup>

## Effects of Multiple Dietary Changes

Despite the potential for substantial reductions in BP from simultaneous implementation of multiple lifestyle interventions, few trials have examined the combined impact of multicomponent interventions. In general, multicomponent intervention studies have documented subadditivity; ie, the combined effect of interventions that implement  $\geq 2$  components is less than the sum of BP reductions from interventions that implement each component alone.<sup>21,57</sup> Despite subadditivity, the BP effects of multicomponent interventions are often large and clinically relevant. One small but tightly controlled trial that enrolled hypertensive adults already on antihypertensive medication tested the effects of a comprehensive program of supervised exercise with provision of prepared meals to accomplish weight loss, sodium reduction, and the DASH diet. The program substantially lowered BP (net reductions in daytime ambulatory systolic and diastolic BPs of 12.1 and 6.6 mm Hg, respectively).<sup>110</sup> A subsequent behavioral intervention trial, PREMIER, tested the effects of the major lifestyle recommendations (weight loss, sodium reduction, increased physical activity, and the DASH diet).<sup>111</sup> In hypertensive participants, none of whom were on medication, mean systolic and diastolic BP reductions were 14.2 and 7.4 mm Hg (6.3 and 3.6 mm Hg, net of control). In nonhypertensive individuals, corresponding BP reductions were 9.2 and 5.8 mm Hg (3.1 and 2.0 mm Hg, net of control).

## Behavioral Interventions to Accomplish Lifestyle Modification

A large number of behavioral intervention trials have tested the effects of dietary change on BP. A variety of theories and models have informed the design of these trials, including social cognitive theory,<sup>112</sup> self-applied behavior modification techniques (behavioral self-management),<sup>113</sup> the relapse prevention model,<sup>114</sup> and the transtheoretical or stages-of-change model.<sup>115</sup> Application of these models and theories often leads to a common intervention approach that emphasizes behavioral skills training, self-monitoring, self-regulation, and motivational interviewing.<sup>116</sup> Typically, these trials enrolled motivated individuals, selected in part because of their self-reported readiness to change. Furthermore, these studies relied on skilled interventionists, often health educators or dietitians, who met frequently with participants. Characteristic findings of these trials are successful behavior change over the short term, typically 6 months, and then recidivism over the long term.

The limited long-term success of intensive behavioral intervention programs highlights the importance of environmental changes that facilitate adoption of desirable lifestyle changes in broad populations. Indeed, even motivated individuals find it difficult to sustain behavior change given powerful cultural forces, societal norms, and commercial interests that encourage a sedentary lifestyle, a suboptimal diet, and overconsumption of calories. Despite these impediments, available evidence from efficacy studies is sufficiently robust and persuasive to advocate dietary change as a means to lower BP and thereby prevent BP-related cardiovascular disease in both nonhypertensive and hypertensive individuals.

## Special Populations

### Children

Elevated BP begins well before adulthood, during the first 2 decades of life and perhaps even earlier, in utero.<sup>117</sup> Numerous observational studies have documented that BP tracks with age from childhood into the adult years.<sup>118–120</sup> Hence, efforts to reduce BP and to prevent the age-related rise in BP in childhood are prudent. The importance of these efforts is highlighted by evidence that BP levels and the prevalence of obesity in children and adolescents 8 to 17 years of age have increased between NHANES surveys conducted in 1988 to 1994 and 1999 to 2000.<sup>16</sup>

The effects of dietary factors on BP have been reviewed by Simons-Morton and Obarzanek.<sup>121</sup> Unfortunately, most studies had methodological limitations, including small sample size, suboptimal BP measurements, and limited experimental contrast. At present, direct evidence from rigorous, well-controlled trials in children and adolescents is sparse. Accordingly, the effect of diet on BP in children and adolescents is, in large part, extrapolated from studies of adults. Such extrapolations are reasonable because elevated BP is a chronic condition resulting from the insidious rise in BP throughout childhood and adulthood.

### Older Persons

Because of the age-related rise in BP that is particularly prominent in middle-aged and older persons and because of the high prevalence of BP-related cardiovascular disease, dietary strategies should be especially beneficial as adults age. Although most diet–BP trials were conducted in middle-aged persons, several were conducted in older persons.<sup>23,122,123</sup> Other trials presented results stratified by age groups. Several important findings emerge. First, older persons can make and sustain dietary changes, specifically weight loss and dietary sodium reduction, over the long term.<sup>23,24</sup> Second, greater BP reductions from dietary interventions occur as individuals get older.<sup>29,30</sup> Third, because of high attributable risk associated with elevated BP in the elderly, the beneficial effects of dietary changes on BP should translate into substantial reductions in cardiovascular risk in the elderly.<sup>124</sup>

### Blacks

On average, blacks have higher BP<sup>4</sup> and are at greater risk of BP-related complications<sup>6–8</sup> than nonblacks. As documented previously in well-controlled efficacy studies, blacks as compared with nonblacks achieve greater BP reduction from several nonpharmacological therapies, specifically sodium reduction, increased potassium intake, and the DASH diet. The potential benefits of these dietary approaches are amplified because survey data indicate that blacks consume high levels of sodium while their potassium intake is less than that of nonblacks.<sup>43</sup> In this setting, the potential benefits of dietary change are substantial and should provide a means to reduce racial disparities in BP and BP-related cardiovascular disease.<sup>125</sup>

### Healthcare Providers

Through advice and by example, physicians can have a powerful influence on their patients' willingness to make



**TABLE 2. Effects of Dietary Factors and Dietary Patterns on BP: A Summary of the Evidence**

	Hypothesized Effect	Evidence
Weight	Direct	++
Sodium chloride (salt)	Direct	++
Potassium	Inverse	++
Magnesium	Inverse	+/-
Calcium	Inverse	+/-
Alcohol	Direct	++
Fat		
Saturated fat	Direct	+/-
Omega-3 polyunsaturated fat	Inverse	++
Omega-6 polyunsaturated fat	Inverse	+/-
Monounsaturated fat	Inverse	+
Protein		
Total protein	Uncertain	+
Vegetable protein	Inverse	+
Animal protein	Uncertain	+/-
Carbohydrate	Direct	+
Fiber	Inverse	+
Cholesterol	Direct	+/-
Dietary patterns		
Vegetarian diets	Inverse	++
DASH-type dietary patterns	Inverse	++

+/- Indicates limited or equivocal evidence; +, suggestive evidence, typically from observational studies and some clinical trials; and ++, persuasive evidence, typically from clinical trials.

dietary lifestyle changes.<sup>126</sup> Although behavioral counseling is often beyond the scope of many office practices, simple assessments (eg, measurement of BMI) and provision of

advice typically is feasible. The success of physician-directed and office-based attempts to achieve lifestyle changes is dependent on several factors, including the skills of the physician and staff, available resources, organizational structure of the office, and the availability of management algorithms that incorporate locally available resources.

Individualized physician-directed lifestyle advice should be based on the patient's willingness to adopt lifestyle changes. Motivated patients should be referred to a skilled dietitian, health educator, or behavioral change program, in large part because success will require frequent visits and contacts. Still, even without the assistance of ancillary personnel and programs, physicians should routinely encourage lifestyle modification.

### Conclusions

A substantial body of evidence strongly supports the concept that multiple dietary factors affect BP. Dietary modifications that effectively lower BP are weight loss, reduced salt intake, increased potassium intake, moderation of alcohol consumption (among those who drink), and consumption of an overall healthy dietary pattern, called the DASH diet (Table 2). Other dietary factors may also affect BP, but the effects are small and/or the evidence is uncertain.

In view of the increasing levels of BP in children and adults and the continuing epidemic of BP-related cardiovascular disease, efforts to reduce BP in both nonhypertensive and hypertensive individuals are warranted. Such efforts will require individuals to change behavior and society to make substantial environmental changes. The current challenge to healthcare providers, researchers, government officials, and the general public is developing and implementing effective clinical and public health strategies that lead to sustained dietary changes among individuals and, more broadly, among populations.

## Writing Group Disclosures

### Writing Group Disclosures

Writing Group Member	Employment	Research Grant	Other Research Support	Speakers Bureau/Honoraria	Ownership Interest	Consultant/Advisory Board	Other
Lawrence J. Appel	Johns Hopkins University	None	None	None	None	None	None
Michael Brands	Medical College of Georgia	None	None	None	None	None	None
Stephen Daniels	Cincinnati Children's Hospital	None	None	None	None	None	None
Njeri Karanja	Kaiser Permanente	None	None	None	None	None	None
Patricia Elmer	Kaiser Permanente	None	None	None	None	None	None
Frank Sacks	Harvard School of Public Health	None	None	None	None	None	None

This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit.

Reviewers' Disclosures

Reviewer Disclosures

Reviewer	Employment	Research Grant	Other Research Support	Speakers Bureau/Honoraria	Ownership Interest	Consultant/Advisory Board	Other
Stephen Havas	University of Maryland School of Medicine	None	None	None	None	NHLBI	None
Theodore Kotchen	Medical College of Wisconsin	NIH	None	None	None	NIH	None
Myron H. Weinberger	Indiana University School of Medicine	None	None	None	None	None	Institute of Medicine's DRI Committee on Sodium, Potassium, and Water (and Sulfate) Intake
Paul K. Whelton	Tulane University Health Sciences Center	None	None	None	None	None	None

This table represents the relationships of reviewer that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all reviewers are required to complete and submit.

References

- Wang Y, Wang QJ. The prevalence of prehypertension and hypertension among US adults according to the new joint national committee guidelines: new challenges of the old problem. *Arch Intern Med.* 2004;164:2126–2134.
- Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB, Levy D. Impact of high-normal blood pressure on the risk of cardiovascular disease. *N Engl J Med.* 2001;345:1291–1297.
- Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D'Agostino RB, Levy D. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. *JAMA.* 2002;287:1003–1010.
- Fields LE, Burt VL, Cutler JA, Hughes J, Roccella EJ, Sorlie P. The burden of adult hypertension in the United States 1999 to 2000: a rising tide. *Hypertension.* 2004;44:398–404.
- Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. *JAMA.* 2003;290:199–206.
- Giles WH, Kittner SJ, Hebel JR, Losonczy KG, Sherwin RW. Determinants of black-white differences in the risk of cerebral infarction: the National Health and Nutrition Examination Survey Epidemiologic Follow-up Study. *Arch Intern Med.* 1995;155:1319–1324.
- Ayala C, Greenlund KJ, Croft JB, Keenan NL, Donehoo RS, Giles WH, Kittner SJ, Marks JS. Racial/ethnic disparities in mortality by stroke subtype in the United States, 1995–1998. *Am J Epidemiol.* 2001;154:1057–1063.
- Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J. Blood pressure and end-stage renal disease in men. *N Engl J Med.* 1996;334:13–18.
- Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, for the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National Heart, Lung, and Blood Institute, National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *Hypertension.* 2003;42:1206–1252.
- Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, for the Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet.* 2002;360:1903–1913.
- Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks: US population data. *Arch Intern Med.* 1993;153:598–615.
- Stamler R. Implications of the INTERSALT study. *Hypertension.* 1991;17(suppl I):I-16–I-20.
- Kotchen TA, McCarron DA. Dietary electrolytes and blood pressure: a statement for healthcare professionals from the American Heart Association Nutrition Committee. *Circulation.* 1998;98:613–617.
- Whelton PK, He J, Appel LJ, Cutler JA, Havas S, Kotchen TA, Roccella EJ, Stout R, Vallbona C, Winston MC, Karimbakas J, for the National High Blood Pressure Education Program Coordinating Committee. Primary prevention of hypertension: clinical and public health advisory from the National High Blood Pressure Education Program. *JAMA.* 2002;288:1882–1888.
- Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999–2000. *JAMA.* 2002;288:1723–1727.
- Muntner P, He J, Cutler JA, Wildman RP, Whelton PK. Trends in blood pressure among children and adolescents. *JAMA.* 2004;291:2107–2113.
- Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. *Hypertension.* 2003;42:878–884.
- Stevens VJ, Corrigan SA, Obarzanek E, Bernauer E, Cook NR, Hebert P, Mattfeldt-Beman M, Oberman A, Sugars C, Dalcin AT, et al. Weight loss intervention in phase I of the Trials of Hypertension Prevention: the TOHP Collaborative Research Group. *Arch Intern Med.* 1993;153:849–858.
- Stevens VJ, Obarzanek E, Cook NR, Lee IM, Appel LJ, Smith West D, Milas NC, Mattfeldt-Beman M, Belden L, Bragg C, Millstone M, Raczynski J, Brewer A, Singh B, Cohen J, for the Trials for the Hypertension Prevention Research Group. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. *Ann Intern Med.* 2001;134:1–11.
- Huang Z, Willett WC, Manson JE, Rosner B, Stampfer MJ, Speizer FE, Colditz GA. Body weight, weight change, and risk for hypertension in women. *Ann Intern Med.* 1998;128:81–88.
- Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure: the Trials of Hypertension Prevention, phase II: the Trials of Hypertension Prevention Collaborative Research Group. *Arch Intern Med.* 1997;157:657–667.
- Langford HG, Blaufox MD, Oberman A, Hawkins CM, Curb JD, Cutter GR, Wassertheil-Smoller S, Pressel S, Babcock C, Abernethy JD, et al. Dietary therapy slows the return of hypertension after stopping prolonged medication. *JAMA.* 1985;253:657–664.
- Whelton PK, Appel LJ, Espeland MA, Applegate WB, Ettinger WH Jr, Kostis JB, Kumanyika S, Lacy CR, Johnson KC, Folmar S, Cutler JA. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled Trial of Nonpharmacologic Interventions in the Elderly (TONE): TONE Collaborative Research Group. *JAMA.* 1998;279:839–846.
- Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, for the Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med.* 2002;346:393–403.
- He FJ, MacGregor GA. Effect of modest salt reduction on blood pressure: a meta-analysis of randomized trials: implications for public health. *J Hum Hypertens.* 2002;16:761–770.

26. Johnson AG, Nguyen TV, Davis D. Blood pressure is linked to salt intake and modulated by the angiotensinogen gene in normotensive and hypertensive elderly subjects. *J Hypertens*. 2001;19:1053–1060.
27. MacGregor GA, Markandu ND, Sagnella GA, Singer DR, Cappuccio FP. Double-blind study of three sodium intakes and long-term effects of sodium restriction in essential hypertension. *Lancet*. 1989;2:1244–1247.
28. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, Obarzanek E, Conlin PR, Miller ER 3rd, Simons-Morton DG, Karanja N, Lin PH, for the DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet: DASH-Sodium Collaborative Research Group. *N Engl J Med*. 2001;344:3–10.
29. Vollmer WM, Sacks FM, Ard J, Appel LJ, Bray GA, Simons-Morton DG, Conlin PR, Svetkey LP, Erlinger TP, Moore TJ, Karanja N, for the DASH-Sodium Trial Collaborative Research Group. Effects of diet and sodium intake on blood pressure: subgroup analysis of the DASH-sodium trial. *Ann Intern Med*. 2001;135:1019–1028.
30. Bray GA, Vollmer WM, Sacks FM, Obarzanek E, Svetkey LP, Appel LJ, for the DASH Collaborative Research Group. A further subgroup analysis of the effects of the DASH diet and three dietary sodium levels on blood pressure: results of the DASH-Sodium Trial. *Am J Cardiol*. 2004;94:222–227.
31. Weir MR, Hall PS, Behrens MT, Flack JM. Salt and blood pressure responses to calcium antagonism in hypertensive patients. *Hypertension*. 1997;30(pt 1):422–427.
32. Appel LJ, Espeland MA, Easter L, Wilson AC, Folmar S, Lacy CR. Effects of reduced sodium intake on hypertension control in older individuals: results from the Trial of Nonpharmacologic Interventions in the Elderly (TONE). *Arch Intern Med*. 2001;161:685–693.
33. Intersalt: an international study of electrolyte excretion and blood pressure: results for 24 hour urinary sodium and potassium excretion: Intersalt Cooperative Research Group. *BMJ*. 1988;297:319–328.
34. He J, Ogden LG, Vupputuri S, Bazzano LA, Loria C, Whelton PK. Dietary sodium intake and subsequent risk of cardiovascular disease in overweight adults. *JAMA*. 1999;282:2027–2034.
35. Tuomilehto J, Jousilahti P, Rastenyte D, Moltchanov V, Tanskanen A, Pietinen P, Nissinen A. Urinary sodium excretion and cardiovascular mortality in Finland: a prospective study. *Lancet*. 2001;357:848–851.
36. He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Dietary sodium intake and incidence of congestive heart failure in overweight US men and women: first National Health and Nutrition Examination Survey Epidemiologic Follow-Up Study. *Arch Intern Med*. 2002;162:1619–1624.
37. Weinberger MH, Miller JZ, Luft FC, Grim CE, Fineberg NS. Definitions and characteristics of sodium sensitivity and blood pressure resistance. *Hypertension*. 1986;8(part 2):II-127–II-134.
38. Obarzanek E, Proschan MA, Vollmer WM, Moore TJ, Sacks FM, Appel LJ, Svetkey LP, Most-Windhauser MM, Cutler JA. Individual blood pressure responses to changes in salt intake: results from the DASH-Sodium trial. *Hypertension*. 2003;42:459–467.
39. He FJ, Markandu ND, MacGregor GA. Importance of the renin system for determining blood pressure fall with acute salt restriction in hypertensive and normotensive whites. *Hypertension*. 2001;38:321–325.
40. Johnson RJ, Herrera-Acosta J, Schreiner GF, Rodriguez-Iturbe B. Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. *N Engl J Med*. 2002;346:913–923.
41. Luft FC, Rankin LI, Bloch R, Weyman AE, Willis LR, Murray RH, Grim CE, Weinberger MH. Cardiovascular and humoral responses to extremes of sodium intake in normal black and white men. *Circulation*. 1979;60:697–706.
42. Morris RC Jr, Sebastian A, Forman A, Tanaka M, Schmidlin O. Normotensive salt sensitivity: effects of race and dietary potassium. *Hypertension*. 1999;33:18–23.
43. Institute of Medicine. *Dietary Reference Intakes: Water, Potassium, Sodium Chloride, and Sulfate*. 1st ed. Washington, DC: National Academy Press; 2004.
44. Mancilha-Carvalho JJ, Souza e Silva NA. The Yanomami Indians in the INTERSALT Study. *Ar Qbras Cardiol*. 2003;80:289–300.
45. Dietary Guidelines Advisory Committee. 2005 Dietary Guidelines Advisory Committee Report. Available at: <http://www.health.gov/dietaryguidelines/dga2005/report/>. Accessed December 5, 2004.
46. Mattes RD, Donnelly D. Relative contributions of dietary sodium sources. *J Am Coll Nutr*. 1991;10:383–393.
47. Havas S, Roccella EJ, Lenfant C. Reducing the public health burden from elevated blood pressure levels in the United States by lowering intake of dietary sodium. *Am J Public Health*. 2004;94:19–22.
48. Cappuccio FP, MacGregor GA. Does potassium supplementation lower blood pressure? A meta-analysis of published trials. *J Hypertens*. 1991;9:465–473.
49. Whelton PK, He J, Cutler JA, Brancati FL, Appel LJ, Follmann D, Klag MJ. Effects of oral potassium on blood pressure: meta-analysis of randomized controlled clinical trials. *JAMA*. 1997;277:1624–1632.
50. Geleijnse JM, Kok FJ, Grobbee DE. Blood pressure response to changes in sodium and potassium intake: a metaregression analysis of randomised trials. *J Hum Hypertens*. 2003;17:471–480.
51. Brancati FL, Appel LJ, Seidler AJ, Whelton PK. Effect of potassium supplementation on blood pressure in African Americans on a low-potassium diet: a randomized, double-blind, placebo-controlled trial. *Arch Intern Med*. 1996;156:61–67.
52. Naismith DJ, Braschi A. The effect of low-dose potassium supplementation on blood pressure in apparently healthy volunteers. *Br J Nutr*. 2003;90:53–60.
53. Obel AO. Placebo-controlled trial of potassium supplements in black patients with mild essential hypertension. *J Cardiovasc Pharmacol*. 1989;14:294–296.
54. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM, Lin PH, Karanja N. A clinical trial of the effects of dietary patterns on blood pressure: DASH Collaborative Research Group. *N Engl J Med*. 1997;336:1117–1124.
55. Karanja NM, Obarzanek E, Lin PH, McCullough ML, Phillips KM, Swain JF, Champagne CM, Hoben KP. Descriptive characteristics of the dietary patterns used in the Dietary Approaches to Stop Hypertension Trial: DASH Collaborative Research Group. *J Am Diet Assoc*. 1999;99:S19–S27.
56. John JH, Ziebland S, Yudkin P, Roe LS, Neil HA, for the Oxford Fruit and Vegetable Study Group. Effects of fruit and vegetable consumption on plasma antioxidant concentrations and blood pressure: a randomised controlled trial. *Lancet*. 2002;359:1969–1974.
57. Chalmers J, Morgan T, Doyle A, Dickson B, Hopper J, Mathews J, Matthews G, Moulds R, Myers J, Nowson C, et al. Australian National Health and Medical Research Council dietary salt study in mild hypertension. *J Hypertens Suppl*. 1986;4:S629–S637.
58. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. *Am J Kidney Dis*. 2004;43(suppl 1):S1–S290.
59. Klatsky AL, Friedman GD, Siegel AB, Gerard MJ. Alcohol consumption and blood pressure Kaiser-Permanente Multiphasic Health Examination data. *N Engl J Med*. 1977;296:1194–1200.
60. Xin X, He J, Frontini MG, Ogden LG, Motsamai OI, Whelton PK. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. *Hypertension*. 2001;38:1112–1117.
61. Okubo Y, Miyamoto T, Suwazono Y, Kobayashi E, Nogawa K. Alcohol consumption and blood pressure in Japanese men. *Alcohol*. 2001;23:149–156.
62. Sacks FM, Rosner B, Kass EH. Blood pressure in vegetarians. *Am J Epidemiol*. 1974;100:390–398.
63. Armstrong B, van Merwyk AJ, Coates H. Blood pressure in Seventh-day Adventist vegetarians. *Am J Epidemiol*. 1977;105:444–449.
64. Sacks FM, Kass EH. Low blood pressure in vegetarians: effects of specific foods and nutrients. *Am J Clin Nutr*. 1988;48:795–800.
65. Rouse IL, Beilin LJ, Armstrong BK, Vandongen R. Blood-pressure-lowering effect of a vegetarian diet: controlled trial in normotensive subjects. *Lancet*. 1983;1:5–10.
66. Margetts BM, Beilin LJ, Vandongen R, Armstrong BK. Vegetarian diet in mild hypertension: a randomised controlled trial. *BMJ (Clin Res Ed)*. 1986;293:1468–1471.
67. Appel LJ, Sacks FM, Carey VJ, Obarzanek E, Swain JF, Miller ER 3rd, Conlin PR, Erlinger TP, Rosner BA, Laranjo NM, Charleston J, McCarron P, Bishop LM, for the OmniHeart Collaborative Research Group. Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial. *JAMA*. 2005;294:2455–2464.
68. Svetkey LP, Simons-Morton D, Vollmer WM, Appel LJ, Conlin PR, Ryan DH, Ard J, Kennedy BM. Effects of dietary patterns on blood pressure: subgroup analysis of the Dietary Approaches to Stop Hyper-



- tension (DASH) randomized clinical trial. *Arch Intern Med.* 1999;159:285–293.
69. Appel LJ, Miller ER 3rd, Seidler AJ, Whelton PK. Does supplementation of diet with “fish oil” reduce blood pressure? A meta-analysis of controlled clinical trials. *Arch Intern Med.* 1993;153:1429–1438.
  70. Morris MC, Sacks F, Rosner B. Does fish oil lower blood pressure? A meta-analysis of controlled trials. *Circulation.* 1993;88:523–533.
  71. Geleijnse JM, Giltay EJ, Grobbee DE, Donders AR, Kok FJ. Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. *J Hypertens.* 2002;20:1493–1499.
  72. Whelton SP, Hyre AD, Pedersen B, Yi Y, Whelton PK, He J. Effect of dietary fiber intake on blood pressure: a meta-analysis of randomized, controlled clinical trials. *J Hypertens.* 2005;23:475–481.
  73. He J, Whelton PK. Effect of dietary fiber and protein intake on blood pressure: a review of epidemiologic evidence. *Clin Exp Hypertens.* 1999;21:785–796.
  74. He J, Streiffer RH, Muntner P, Krousel-Wood MA, Whelton PK. Effect of dietary fiber intake on blood pressure: a randomized, double-blind, placebo-controlled trial. *J Hypertens.* 2004;22:73–80.
  75. Cappuccio FP, Elliott P, Allender PS, Pryer J, Follman DA, Cutler JA. Epidemiologic association between dietary calcium intake and blood pressure: a meta-analysis of published data. *Am J Epidemiol.* 1995;142:935–945.
  76. Allender PS, Cutler JA, Follmann D, Cappuccio FP, Pryer J, Elliott P. Dietary calcium and blood pressure: a meta-analysis of randomized clinical trials. *Ann Intern Med.* 1996;124:825–831.
  77. Bucher HC, Cook RJ, Guyatt GH, Lang JD, Cook DJ, Hatala R, Hunt DL. Effects of dietary calcium supplementation on blood pressure: a meta-analysis of randomized controlled trials. *JAMA.* 1996;275:1016–1022.
  78. Griffith LE, Guyatt GH, Cook RJ, Bucher HC, Cook DJ. The influence of dietary and nondietary calcium supplementation on blood pressure: an updated metaanalysis of randomized controlled trials. *Am J Hypertens.* 1999;12:84–92.
  79. Zemel MB, Gualdoni SM, Sowers JR. Sodium excretion and plasma rennin activity in normotensive and hypertensive black adults as affected by dietary calcium and sodium. *J Hypertens.* 1986;4:343S–345S.
  80. Saito K, Sano H, Furuta Y, Fukuzaki H. Effect of oral calcium on blood pressure response in salt-loaded borderline hypertensive patients. *Hypertension.* 1989;13:219–226.
  81. Rich GM, McCullough M, Olmedo A, Malarick C, Moore TJ. Blood pressure and renal blood flow responses to dietary calcium and sodium intake in humans. *Am J Hypertens.* 1991;4:642S–645S.
  82. Mizushima S, Cappuccio FP, Nichols R, Elliott P. Dietary magnesium intake and blood pressure: a qualitative overview of the observational studies. *J Hum Hypertens.* 1998;12:447–453.
  83. Jee SH, Miller ER 3rd, Guallar E, Singh VK, Appel LJ, Klag MJ. The effect of magnesium supplementation on blood pressure: a meta-analysis of randomized clinical trials. *Am J Hypertens.* 2002;15:691–696.
  84. Hodges RE, Rebello T. Carbohydrates and blood pressure. *Ann Intern Med.* 1983;98(pt 2):838–841.
  85. Stamler J, Caggiula A, Grandits GA, Kjelsberg M, Cutler JA. Relationship to blood pressure of combinations of dietary macronutrients: findings of the Multiple Risk Factor Intervention Trial (MRFIT). *Circulation.* 1996;94:2417–2423.
  86. Reed D, McGee D, Yano K, Hankin J. Diet, blood pressure, and multicollinearity. *Hypertension.* 1985;7:405–410.
  87. Stamler J, Liu K, Ruth KJ, Pryer J, Greenland P. Eight-year blood pressure change in middle-aged men: relationship to multiple nutrients. *Hypertension.* 2002;39:1000–1006.
  88. Morris MC. Dietary fats and blood pressure. *J Cardiovasc Risk.* 1994;1:21–30.
  89. Rebello T, Hodges RE, Smith JL. Short-term effects of various sugars on antinatriuresis and blood pressure changes in normotensive young men. *Am J Clin Nutr.* 1983;38:84–94.
  90. Israel KD, Michaelis OE 4th, Reiser S, Keeney M. Serum uric acid, inorganic phosphorus, and glutamic-oxalacetic transaminase and blood pressure in carbohydrate-sensitive adults consuming three different levels of sucrose. *Ann Nutr Metab.* 1983;27:425–435.
  91. Visvanathan R, Chen R, Horowitz M, Chapman I. Blood pressure responses in healthy older people to 50 g carbohydrate drinks with differing glycaemic effects. *Br J Nutr.* 2004;92:335–340.
  92. Pereira MA, Swain J, Goldfine AB, Rifai N, Ludwig DS. Effects of a low-glycemic load diet on resting energy expenditure and heart disease risk factors during weight loss. *JAMA.* 2004;292:2482–2490.
  93. Ascherio A, Rimm EB, Giovannucci EL, Colditz GA, Rosner B, Willett WC, Sacks F, Stampfer MJ. A prospective study of nutritional factors and hypertension among US men. *Circulation.* 1992;86:1475–1484.
  94. Ascherio A, Hennekens C, Willett WC, Sacks F, Rosner B, Manson J, Witteman J, Stampfer MJ. Prospective study of nutritional factors, blood pressure, and hypertension among US women. *Hypertension.* 1996;27:1065–1072.
  95. Rasmussen OW, Thomsen C, Hansen KW, Vesterlund M, Winther E, Hermansen K. Effects on blood pressure, glucose, and lipid levels of a high-monounsaturated fat diet compared with a high-carbohydrate diet in NIDDM subjects. *Diabetes Care.* 1993;16:1565–1571.
  96. Ferrara LA, Raimondi AS, d’Episcopo L, Guida L, Dello Russo A, Marotta T. Olive oil and reduced need for antihypertensive medications. *Arch Intern Med.* 2000;160:837–842.
  97. Obarzanek E, Velletri PA, Cutler JA. Dietary protein and blood pressure. *JAMA.* 1996;275:1598–1603.
  98. Elliott P, Stamler J, Appel L, Dennis B, Dyer AR, Kesteloot H, Ueshima H, Okayama A, Obarzanek E, Chan Q, Zhou B, for the INTERMAP Cooperative Research Group. Relationship of dietary protein to blood pressure: the INTERMAP Study. *Arch Intern Med.* In press.
  99. Teede HJ, Dalais FS, Kotsopoulos D, Liang YL, Davis S, McGrath BP. Dietary soy has both beneficial and potentially adverse cardiovascular effects: a placebo-controlled study in men and postmenopausal women. *J Clin Endocrinol Metab.* 2001;86:3053–3060.
  100. Burke V, Hodgson JM, Beilin LJ, Giangiulio N, Rogers P, Puddey IB. Dietary protein and soluble fiber reduce ambulatory blood pressure in treated hypertensives. *Hypertension.* 2001;38:821–826.
  101. He J, Gu D, Wu X, Chen J, Duan X, Chen J, Whelton PK. Effect of soybean protein on blood pressure: a randomized, controlled trial. *Ann Intern Med.* 2005;143:1–9.
  102. Ness AR, Chee D, Elliott P. Vitamin C and blood pressure: an overview. *J Hum Hypertens.* 1997;11:343–350.
  103. Kim MK, Sasaki S, Sasazuki S, Okubo S, Hayashi M, Tsugane S. Lack of long-term effect of vitamin C supplementation on blood pressure. *Hypertension.* 2002;40:797–803.
  104. Lifton RP, Wilson FH, Choate KA, Geller DS. Salt and blood pressure: new insight from human genetic studies. *Cold Spring Harb Symp Quant Biol.* 2002;67:445–450.
  105. Hunt SC, Cook NR, Oberman A, Cutler JA, Hennekens CH, Allender PS, Walker WG, Whelton PK, Williams RR. Angiotensinogen genotype, sodium reduction, weight loss, and prevention of hypertension: trials of hypertension prevention, phase II. *Hypertension.* 1998;32:393–401.
  106. Hunt SC, Geleijnse JM, Wu LL, Witteman JC, Williams RR, Grobbee DE. Enhanced blood pressure response to mild sodium reduction in subjects with the 235T variant of the angiotensinogen gene. *Am J Hypertens.* 1999;12:460–466.
  107. Svetkey LP, Moore TJ, Simons-Morton DG, Appel LJ, Bray GA, Sacks FM, Ard JD, Mortensen RM, Mitchell SR, Conlin PR, Kesari M, for the DASH Collaborative Research Group. Angiotensinogen genotype and blood pressure response in the Dietary Approaches to Stop Hypertension (DASH) study. *J Hypertens.* 2001;19:1949–1956.
  108. Grant FD, Romero JR, Jeunemaitre X, Hunt SC, Hopkins PN, Hollenberg NH, Williams GH. Low-renin hypertension, altered sodium homeostasis, and an alpha-adducin polymorphism. *Hypertension.* 2002;39:191–196.
  109. Kostis JB, Wilson AC, Hooper WC, Harrison KW, Philipp CS, Appel LJ, Espeland MA, Folmar S, Johnson KC, for the TONE Cooperative Research Group. Trial of Nonpharmacologic Interventions in the Elderly: association of angiotensin-converting enzyme DD genotype with blood pressure sensitivity to weight loss. *Am Heart J.* 2002;144:625–629.
  110. Miller ER 3rd, Erlinger TP, Young DR, Jehn M, Charleston J, Rhodes D, Wasan SK, Appel LJ. Results of the Diet, Exercise, and Weight Loss Intervention Trial (DEW-IT). *Hypertension.* 2002;40:612–618.
  111. Appel LJ, Champagne CM, Harsha DW, Cooper LS, Obarzanek E, Elmer PJ, Stevens VJ, Vollmer WM, Lin PH, Svetkey LP, Stedman SW, Young DR, for the Writing Group of the PREMIER Collaborative Research Group. Effects of comprehensive lifestyle modifi-

- cation on blood pressure control: main results of the PREMIER clinical trial. *JAMA*. 2003;289:2083–2093.
112. Bandura A. *Social Foundations of Thought and Action: A Social Cognitive Theory*. 1st ed. Englewood Cliffs, NJ: Prentice Hall; 1986.
  113. Watson DL, Tharp RG. *Self-Directed Behavior: Self-Modification for Personal Adjustment*. 5th ed. Pacific Grove, Calif: Brooks/Cole; 1989.
  114. Marlatt GA, Gordon JR. *Relapse Prevention: Maintenance Strategies in the Treatment of Addictive Behaviors*. 1st ed. New York, NY: Guilford Press; 1985.
  115. Prochaska JO, DiClemente CC. Stages and processes of self-change of smoking: toward an integrative model of change. *J Consult Clin Psychol*. 1983;51:390–395.
  116. Miller WR, Rollnick S. *Motivational Interviewing: Preparing People to Change Addictive Behavior*. 1st ed. New York, NY: Guilford Press; 1991.
  117. Barker DJ, Osmond C, Golding J, Kuh D, Wadsworth ME. Growth in utero, blood pressure in childhood and adult life, and mortality from cardiovascular disease. *BMJ*. 1989;298:564–567.
  118. Gillman MW, Cook NR, Rosner B, Evans DA, Keough ME, Taylor JO, Hennekens CH. Identifying children at high risk for the development of essential hypertension. *J Pediatr*. 1993;122:837–846.
  119. Bao W, Threefoot SA, Srinivasan SR, Berenson GS. Essential hypertension predicted by tracking of elevated blood pressure from childhood to adulthood: the Bogalusa Heart Study. *Am J Hypertens*. 1995;8:657–665.
  120. Dekkers JC, Snieder H, Van Den Oord EJ, Treiber FA. Moderators of blood pressure development from childhood to adulthood: a 10-year longitudinal study. *J Pediatr*. 2002;141:770–779.
  121. Simons-Morton DG, Obarzanek E. Diet and blood pressure in children and adolescents. *Pediatr Nephrol*. 1997;11:244–249.
  122. Applegate WB, Miller ST, Elam JT, Cushman WC, el Derwi D, Brewer A, Graney MJ. Nonpharmacologic intervention to reduce blood pressure in older patients with mild hypertension. *Arch Intern Med*. 1992;152:1162–1166.
  123. Cappuccio FP, Markandu ND, Carney C, Sagnella GA, MacGregor GA. Double-blind randomised trial of modest salt restriction in older people. *Lancet*. 1997;350:850–854.
  124. Klag MJ, Whelton PK, Appel LJ. Effect of age on the efficacy of blood pressure treatment strategies. *Hypertension*. 1990;16:700–705.
  125. Erlinger TP, Vollmer WM, Svetkey LP, Appel LJ. The potential impact of nonpharmacologic population-wide blood pressure reduction on coronary heart disease events: pronounced benefits in African-Americans and hypertensives. *Prev Med*. 2003;37:327–333.
  126. Miller ER Jr, Erlinger TP, Young DR, Prokopowicz GP, Appel LJ. Lifestyle changes that reduce blood pressure: implementation in clinical practice. *J Clin Hypertens (Greenwich)*. 1999;1:191–198.

## Dietary Approaches to Prevent and Treat Hypertension: A Scientific Statement From the American Heart Association

Lawrence J. Appel, Michael W. Brands, Stephen R. Daniels, Njeri Karanja, Patricia J. Elmer and Frank M. Sacks

*Hypertension*. 2006;47:296-308

doi: 10.1161/01.HYP.0000202568.01167.B6

*Hypertension* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231

Copyright © 2006 American Heart Association, Inc. All rights reserved.

Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://hyper.ahajournals.org/content/47/2/296>

**Permissions:** Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Hypertension* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the [Permissions and Rights Question and Answer](#) document.

**Reprints:** Information about reprints can be found online at:  
<http://www.lww.com/reprints>

**Subscriptions:** Information about subscribing to *Hypertension* is online at:  
<http://hyper.ahajournals.org/subscriptions/>